Oncomfort announces a newly composed Board of Directors along with raising €10m Series A funding co-led by Debiopharm and Crédit Mutuel Innovation

– BELGIUM, Wavre –  Oncomfort, the Belgian inventor of and leader in Digital Sedation – a new method for relieving patients’ pain and anxiety without medication – today announced the completion of a €10 million Series A funding round co-led by two prominent institutional investors: Debiopharm and Crédit Mutuel Innovation.

Oncomfort has raised no less than €10 million in a Series A funding round. It plans to use this investment to develop its Digital Sedation solution and accelerate its international expansion on the European and American markets.

The investment round was realized with two leading institutional investors: the Swiss Debiopharm, and the French Crédit Mutuel Innovation. The investment includes continuing support from Wallonia Innovation and Growth and the existing investors.

Both institutional investors will join Oncomfort’s newly composed Board of Directors.

Founded in 2017, Oncomfort is a Belgian scale-up specialized in Digital Sedation, a completely new method for relieving patients’ pain and anxiety through treatment with clinically proven sessions of therapeutic Virtual Reality. Since the launch of the Sedakit for Digital Sedation in Benelux and France in June 2019, over 30,000 patients have been treated and have had their pain and anxiety relieved before, during, and after interventions in many clinical fields such as anesthesia, oncology, interventional radiology and cardiology, as well as pediatrics.

“We are at a tipping point in our digital therapy,” said CEO, Mario Huyghe. “The medical community has discovered the advantages and potential of Digital Sedation to relieve pain and anxiety without medication. Virtual Reality acts as an enabler for this digital therapy. Yet, Oncomfort’s true potential comes from the scientific evidence of its digital sedation and the multidisciplinary co-creation with the expertise of anesthesiologists, neurologists, psychologists, and hypnotherapists. With this Series A funding, we will accelerate our product development with a broader engineering team and invest in the international expansion of Oncomfort.”

“We are delighted to find a scientifically validated digital tool to support the overall journey of patients, which frequently includes various levels of pain, anxiety, and fear. The fact that advanced Virtual Reality in combination with hypnotherapy and integrative therapeutic techniques can be used to effectively sedate patients is truly impressive and offers an interesting option for patients to find physical and emotional relief,” explained Thierry Mauvernay, President of Debiopharm.

“Our investment in Oncomfort’s digital sedation solution is based on the strong potential of digital therapeutics as well as the specific intellectual property and scientific evidence that Oncomfort has built over recent years,” continued Karine Lignel, CEO of Crédit Mutuel Innovation.

“With this investment in Oncomfort, we want to push the boundaries to inspire healthcare stakeholders to acknowledge that there is much more we can do for patients through digital technology,” said Tanja Dowe, CEO of Debiopharm Innovation Fund.

“We were convinced, on the one hand, by the scientific results and the technological developments already achieved by Oncomfort, that will enable an even more personalized patient care thanks to the upcoming new features of the Sedakit, and on the other hand by the high level of the team and its partners. With this long-term investment, we are committed to supporting Oncomfort’s team to unleash its potential in the European and American market,” commented Delphine Cardi, Director of Participations, and Tanguy Besson, Associate at Crédit Mutuel Innovation.

For more information: https://www.oncomfort.com/en

About Debiopharm

Debiopharm develops, manufactures, and invests in innovative therapies and technologies that respond to high unmet medical needs in oncology and bacterial infections. Through our digital health investments, we provide funding and strategic guidance for companies with an ambition to improve the patient journey and reimagine how clinical trials are conducted. Our growing portfolio company achievements include 10 FDA clearances, 13 CE marks, 2 IPOs, and 4 trade exits. Since 2008, we have invested over USD 120 million, typically leading the investment rounds of our 16 portfolio companies.

For more information: https://www.debiopharm.com/digital-health/

About Crédit Mutuel Innovation

Crédit Mutuel Innovation is the venture capital subsidiary of Crédit Mutuel Equity, a member of Crédit Mutuel Alliance Fédérale. Its objective is to invest in companies developing promising technologies. Crédit Mutuel Innovation selects companies with strong growth potential in dynamic sectors such as information technology, telecommunications, electronics, life sciences, new materials and environment. For more than 15 years, Crédit Mutuel Innovation has invested – and often reinvests – its own capital to support innovative companies to their market. Crédit Mutuel Innovation’s policy is to provide long-term equity support to innovative startups to streamline their chances of success.

For more information: https://www.creditmutuel-equity.eu/fr/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.